Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Has Roger learned his lesson?

<< Previous

Bullboard Posts

Next >>

Comment by TommyNickelson Oct 25, 2024 6:11am

125 Views

Post# 36281552

RE:RE:RE:RE:Has Roger learned his lesson?

From what I know, the extra FDA data requests stem from the July 2023 response to Theralase's pre-BTD. It doesn't explain why Roger expected to file a 2nd pre-BTD in Q1 of 2024. Did he always know that the next filing would be 4 or 5 quarters after but strung along investors in order to get the funding needed to be able to re-file? In other words, in his mind, the end justifies the means?

And if he does get BTD approval in December, was he correct in his approach?

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland